A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

The brain-computer interface developer Synchron has laid out plans to build an artificial intelligence model trained on the language of cognition—instead of words or pictures—with programs that are ...

Empress Therapeutics is halving its team, letting go of 23 employees as the biotech works to get its small-molecule science ...

Quest Diagnostics announced it is teaming up with Google Cloud to develop artificial intelligence programs that can ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

J&J will now pick up almost the full tab for the phase 3 trial, and, in return, Nanobiotix will see the potential milestone ...